Therapeutic strategies for neurodegenerative disorders have commonly targeted individual
aspects of the disease pathogenesis to little success. Neurodegenerative diseases …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Insulin is a peptide secreted by the pancreas and plays an important role in the regulation of
glucose metabolism in peripheral tissues. Although the role of insulin in the periphery is well …

Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …

Introduction People with type 2 diabetes have increased risk of dementia. Glucagon‐like
peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for …

Ever since the brain was identified as an insulin-sensitive organ, evidence has rapidly
accumulated that insulin action in the brain produces multiple behavioral and metabolic …

Neuropsychiatric disorders are multifactorial disorders with diverse aetiological factors.
Identifying treatment targets is challenging because the diseases are resulting from …

Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis
of brain impairment caused by chronic hyperglycemia is complex and includes …

In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD). We
hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation …